BREAKING: Core CPI Steady, Jobless Claims Highest Since Oct. 2021Shares of Maze Therapeutics (MAZE) catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.Leerink Partners analyst Joseph Schwartz said Maze could have a best-in-class treatment for phenylketonuria, or PKU. In this condition, the body can't break down phenylalanine, an essential amino acid. The buildup of phenylalanine can lead to intellectual disability, seizures, small head s ...